Clinical trials: Immunodeficiency
HIV
A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK) of dolutegravir (DTG) in infants born to mothers living with HIV-1.
- Trial name
- NCT05406583
- Testing
- Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose)
- Where
- 15 sites in United States, South Africa and 1 more
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Malignant Solid Neoplasm, HIV Infection
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and…
- Conditions
- Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT01822522
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 20 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Human Immunodeficiency Virus, HIV Infections
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine…
- Trial name
- NCT01910402
- Testing
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir
- Where
- 90 sites in United States, Argentina and 11 more
- Volunteers
- 499 people
- Sponsor
- ViiV Healthcare
HIV/AIDS
PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS
While major advancements in medical technology over the past decade have significantly improved the life expectancy of persons infected with human immunodeficiency virus (HIV), HIV-positive youth today face new barriers to the…
- Trial name
- NCT03758066
- Testing
- PlusCare
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.
Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
The primary purpose of this study is to assess the rate of early discontinuation from randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason other than confirmation of the negative HIV…
- Trial name
- PEPDar (NCT01516970)
- Testing
- Darunavir/Ritonavir (DRV/r), Lopinavir in fixed combination with Ritonavir, Zidovudine
- Where
- 17 sites in Germany
- Volunteers
- 312 people
- Sponsor
- Janssen-Cilag G.m.b.H
HIV Infections
Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.
- Trial name
- RACING (NCT01048671)
- Testing
- Raltegravir, ARV (non-raltegravir)
- Volunteers
- 482 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Perinatal Depression
Adaptation of the Friendship Bench Intervention for HIV-infected Perinatal Women in Lilongwe
In many sub-Saharan African countries, the scale-up of lifelong antiretroviral treatment (ART) to all pregnant and breastfeeding women under Option B+ has the potential to radically improve maternal health and reduce…
- Trial name
- Periscope (NCT04143009)
- Testing
- Enhanced Friendship Bench, Enhanced Standard Care (Control), Adapted Friendship Bench
- Where
- 3 sites in Malawi
- Volunteers
- 92 people
- Sponsor
- University of North Carolina, Chapel Hill
Alcohol Use, Unspecified, HIV/AIDS
Mobile Technology to Extend Clinic-based Counseling for HIV+s in Uganda
The EXTEND study is a randomized controlled trial to compare the uptake and acceptability, efficacy, and cost of methods of delivery of an alcohol intervention in reducing unhealthy alcohol use and increasing viral suppression…
- Trial name
- EXTEND (NCT03928418)
- Testing
- In-person counseling session, Live phone call booster session, Technology (IVR or SMS) booster session
- Where
- Uganda
- Volunteers
- 272 people
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus
Pre-exposure Prophylaxis Implementation in Central-Eastern European Countries
To stem increasing rates of HIV among gay and bisexual men in Central-Eastern Europe, the feasibility, acceptability, and early efficacy of a culturally adapted evidence-based program to introduce pre-exposure prophylaxis (PrEP)…
- Trial name
- NCT05323123
- Testing
- SPARK, HealthMpowerment, PrEP Education
- Where
- 3 sites in United States, Romania
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hiv, Fatigue
High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV
This is a multi-site, randomized, single-blind (researchers), active treatment concurrent control trial with individuals aged 50-80 living with HIV who experience fatigue and live a sedentary lifestyle.
- Conditions
- Hiv, Fatigue, Mobility Limitation
- Trial name
- HEALTH (NCT04550676)
- Testing
- HIIT (intervention), CME (active control), Coaching
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- University of Colorado, Denver
HIV Facial Lipoatrophy
Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy
The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment…
- Trial name
- NCT02342223
- Testing
- Voluma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jared Jagdeo, MD, MS
Infection, Human Immunodeficiency Virus, HIV Infections
GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
Human immuno deficiency virus 1 (HIV-1) infections continues to be a serious health threat throughout the world and development of medicines with new mechanism of action have an important role to play.
- Trial name
- NCT03231943
- Testing
- GSK3640254
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hiv
Autologous CD4 T-Cells in HIV (C34-CXCR4)
A single cohort, open-label pilot study of the safety and tolerability of a single infusion of autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector in…
- Trial name
- NCT03020524
- Testing
- Autologous CD4 T-Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Cardiovascular Disease, HIV
Statin Therapy to Improve Atherosclerosis in HIV Patients
In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less vulnerable, will deter plaque progression, and improve endothelial function.
- Conditions
- Cardiovascular Disease, HIV, Atherosclerosis, Inflammation
- Trial name
- NCT00965185
- Testing
- atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
HIV-1 Infection, HIV Infections
A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.
- Trial name
- NCT01000818
- Testing
- MK0518 (Raltegravir), famotidine, omeprazole
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in the treatment of immune deficiencies and…
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome
- Trial name
- NCT00176826
- Testing
- Stem Cell Transplant, Myeloablative conditioning regimen
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
This trial develops a health-related symptom index for participants with and either treated or monitored for anal high-grade squamous intraepithelial lesions.
- Trial name
- NCT04276935
- Testing
- Interview, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infection
HIV Reservoir Reduction With Interleukin-2
The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV…
- Trial name
- IL2 (NCT03308786)
- Testing
- Recombinant Interleukin-2
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Western Reserve University
HIV-1
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
The purpose of the protocol is to assess long-term safety and tolerability of subjects who discontinue for any reason from UK-453,061 qualifying studies.
- Trial name
- NCT00824369
- Testing
- No drug will be administered
- Where
- 27 sites in United States, Argentina and 10 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Hereditary Angioedema (HAE)
Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
This 3-part study will evaluate the safety and efficacy of an oral treatment, BCX7353, in preventing angioedema attacks in subjects with hereditary angioedema (HAE).
- Trial name
- APeX-1 (NCT02870972)
- Testing
- BCX7353
- Where
- 24 sites in Australia, Austria and 9 more
- Volunteers
- 75 people
- Sponsor
- BioCryst Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.